Acrivon Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q3 2024.
  • Acrivon Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$22.4M, a 55.1% decline year-over-year.
  • Acrivon Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$77M, a 53.8% decline year-over-year.
  • Acrivon Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$60.4M, a 93.8% decline from 2022.
  • Acrivon Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$31.2M, a 91.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$77M -$22.4M -$7.98M -55.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$69M -$18.8M -$4.88M -35.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$64.1M -$16.5M -$3.73M -29.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$60.4M -$19.3M -$10.3M -116% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$50.1M -$14.5M -$5.27M -57.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$44.8M -$13.9M -$8.09M -139% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$36.7M -$12.8M -$5.54M -76.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$31.2M -$8.93M -$4.59M -106% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$26.6M -$9.2M -$6.76M -277% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$19.8M -$5.82M -$3.27M -128% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$16.6M -$7.22M -$308K -4.46% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$16.2M -$4.34M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 -$2.44M Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-15
Q2 2021 -$2.55M Apr 1, 2021 Jun 30, 2021 10-Q 2022-12-15
Q1 2021 -$6.91M Jan 1, 2021 Mar 31, 2021 10-Q 2022-12-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.